Technical Analysis for ITCI - Intra-Cellular Therapies Inc.
|Grade||Last Price||% Change||Price Change|
ITCI closed down 0.48 percent on Friday, January 18, 2019, on 1.33 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
|Weak or Absent||Down||Down||Down|
|See historical ITCI trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Hammer Candlestick||Bullish||0.00%|
|Jan 18||NR7||Range Contraction||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 18||Down 3 Days in a Row||Weakness||0.00%|
|Jan 17||Weak + Overbought||Other||-0.48%|
|Jan 17||Wide Bands||Range Expansion||-0.48%|
|Jan 17||Overbought Stochastic||Strength||-0.48%|
|Jan 16||Weak + Overbought||Other||-4.05%|
|Jan 16||Wide Bands||Range Expansion||-4.05%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ITCI news...
|52 Week High||25.82|
|52 Week Low||10.21|
|200-Day Moving Average||18.6962|
|50-Day Moving Average||14.0654|
|20-Day Moving Average||12.0285|
|10-Day Moving Average||12.902|
|Average True Range||0.8299|
|Chandelier Exit (Long, 3 ATRs )||11.1003|
|Chandelier Exit (Short, 3 ATRs )||12.6997|
|Upper Bollinger Band||13.9327|
|Lower Bollinger Band||10.1243|
|Percent B (%b)||0.64|
|MACD Signal Line||-0.4584|
|Market Cap||544.97 Million|
|Num Shares||43.4 Million|
|Price-to-Earnings (P/E) Ratio||-5.32|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||13.29|
|Resistance 3 (R3)||13.26||12.99||13.16|
|Resistance 2 (R2)||12.99||12.80||13.00||13.12|
|Resistance 1 (R1)||12.77||12.69||12.64||12.80||13.08|
|Support 1 (S1)||12.28||12.31||12.15||12.31||12.02|
|Support 2 (S2)||12.01||12.20||12.02||11.98|
|Support 3 (S3)||11.79||12.01||11.94|
|Support 4 (S4)||11.82|